Afficher la notice abrégée

Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorSAMIER FOUBERT, Alexandra
dc.contributor.authorTRAON, A. P.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGUILLET, Florian
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLE GOFF, Melanie
ORCID: 0000-0003-2848-6287
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorHELMER, Catherine
dc.contributor.authorTISON, F.
dc.contributor.authorRASCOL, O.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPROUST-LIMA, Cecile
dc.contributor.authorMEISSNER, W. G.
dc.date.accessioned2021-01-25T14:26:19Z
dc.date.available2021-01-25T14:26:19Z
dc.date.issued2020
dc.identifier.issn1095-953X (Electronic) 0969-9961 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/25987
dc.description.abstractEnMultiple system atrophy (MSA) is a rare neurodegenerative disease, with limited understanding of disease progression and prognostic factors. We leveraged the data of a large prospective cohort of MSA to study both clinical progression and survival and assess their determinants. All consecutive patients seen at the French Reference Centre for MSA since 2007 were included in a prospective cohort with an annual follow-up including the Unified MSA Rating Scale (UMSARS). We used joint models to evaluate the risk of death, the mean trajectory of each UMSARS subscale and to determine the potential factors. Investigated factors included gender, age at baseline, MSA subtype, diagnosis certainty, type of first symptoms and the duration between symptom onset and the first visit. Among the 261 MSA patients included in our cohort, the median duration of clinical follow-up was 2.1 years (up to 10.3 years) and the median survival was 4.0 years since the first visit. Main factors for poor survival were the progression over time of UMSARS score (I + II and IV) and the severity of orthostatic hypotension. MSA subtype had no effect on progression or survival. The UMSARS I + II score progressed faster over time in subjects with autonomic dysfunction as the initial feature and in women. Despite a faster progression, women and men had similar survival. From this large MSA cohort, we confirm the rapid progression and poor prognosis of MSA. We provide additional evidence for a negative impact of early autonomic dysfunction and the severity of orthostatic hypotension on both disease progression and survival.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectSEPIA
dc.subjectLEHA
dc.subjectBiostatistics
dc.title.enDisease progression and prognostic factors in multiple system atrophy: A prospective cohort study
dc.title.alternativeNeurobiol Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.nbd.2020.104813en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32087288en_US
bordeaux.journalNeurobiology of Diseaseen_US
bordeaux.page104813en_US
bordeaux.volume139en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamSEPIAen_US
bordeaux.teamLEHA_BPH
bordeaux.teamBIOSTAT_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03120476
hal.version1
hal.date.transferred2021-01-25T14:26:24Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurobiology%20of%20Disease&rft.date=2020&rft.volume=139&rft.spage=104813&rft.epage=104813&rft.eissn=1095-953X%20(Electronic)%200969-9961%20(Linking)&rft.issn=1095-953X%20(Electronic)%200969-9961%20(Linking)&rft.au=SAMIER%20FOUBERT,%20Alexandra&TRAON,%20A.%20P.&GUILLET,%20Florian&LE%20GOFF,%20Melanie&HELMER,%20Catherine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_ND_2020_Foubert-Samier.pdf
Taille:
2.023Mo
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée